OncoTherapy Science, Inc.
4564.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥7,312,028 | ¥4,255,669 | ¥9,054,254 | ¥12,935,172 |
| - Cash | ¥833,883 | ¥527,656 | ¥1,117,635 | ¥1,836,906 |
| + Debt | ¥51,067 | ¥106,849 | ¥0 | ¥0 |
| Enterprise Value | ¥6,529,212 | ¥3,834,862 | ¥7,936,619 | ¥11,098,266 |
| Revenue | ¥750,048 | ¥610,118 | ¥1,134,903 | ¥1,153,663 |
| % Growth | 22.9% | -46.2% | -1.6% | – |
| Gross Profit | -¥12,756 | -¥177,718 | ¥41,685 | ¥113,912 |
| % Margin | -1.7% | -29.1% | 3.7% | 9.9% |
| EBITDA | -¥811,924 | -¥1,285,493 | -¥1,091,000 | -¥2,037,000 |
| % Margin | -108.2% | -210.7% | -96.1% | -176.6% |
| Net Income | -¥815,285 | -¥1,288,138 | -¥1,118,644 | -¥2,571,541 |
| % Margin | -108.7% | -211.1% | -98.6% | -222.9% |
| EPS Diluted | -3.12 | -6.05 | -5.81 | -13.72 |
| % Growth | 48.4% | -4.1% | 57.7% | – |
| Operating Cash Flow | -¥815,021 | -¥1,227,990 | -¥794,901 | -¥2,073,224 |
| Capital Expenditures | -¥279 | -¥2,627 | -¥5,393 | -¥456,949 |
| Free Cash Flow | -¥815,300 | -¥1,230,617 | -¥800,294 | -¥2,530,173 |